Camostat mesylate is a serine protease inhibitor classified as a peptidomimetic agent, primarily approved for the treatment of acute pancreatitis through the inhibition of trypsin and other proteases involved… Read more
Camostat mesylate is a serine protease inhibitor classified as a peptidomimetic agent, primarily approved for the treatment of acute pancreatitis through the inhibition of trypsin and other proteases involved in tissue damage. Beyond its therapeutic role in pancreatitis, this compound is researched for potential applications in treating certain cancers, viral infections, and fibrosis in liver or kidney disease. The listed products, including the active pharmaceutical ingredient, identified impurities, and stable isotope labelled compounds, serve as critical reference standards for pharmaceutical laboratories. These materials are essential for accurate impurity profiling and method validation, ensuring high-quality analytical testing during drug development and quality control. Laboratories utilize these reference standards to reliably quantify degradation products and metabolites, supporting regulatory compliance and the rigorous assessment of drug purity and safety.